Verrica Pharmaceuticals Inc. 8-K

What Happened

• Verrica Pharmaceuticals, Inc. announced in an 8-K filed June 9, 2026 that its stockholders approved the Verrica Pharmaceuticals, Inc. Amended and Restated 2018 Equity Incentive Plan at the company’s 2026 Annual Meeting. The Plan had been previously approved by the Board subject to stockholder approval and became effective immediately upon that approval.
• The company’s definitive proxy statement for the Annual Meeting (filed April 20, 2026) contains a summary of the Plan (Proposal 4, beginning on page 21), and the full text of the Amended and Restated 2018 Equity Incentive Plan is filed as Exhibit 10.1 to the Form 8‑K.

Key Details

• Filing date of this Form 8‑K: June 9, 2026.
• Proxy Statement with Plan summary filed April 20, 2026 (see Proposal 4, p.21).
• The Amended and Restated 2018 Equity Incentive Plan became effective immediately upon stockholder approval.
• Full plan text is included as Exhibit 10.1 to the 8‑K.

Why It Matters

• Approval of the amended equity incentive plan authorizes the company to grant stock-based awards under the updated plan terms, which affects how Verrica can compensate and incentivize employees, directors and consultants going forward.
• For shareholders, an updated equity plan can influence potential dilution and executive incentives; investors should review the Plan summary in the Proxy Statement and the full Exhibit 10.1 to understand share reserve, award types, and any limits or changes.